Overall, we conclude that the inhibition of HDAC6 can downregulate CMA and thereby ameliorate rheumatoid arthritis HDAC6 may be a new potential target for the clinical treatment of rheumatoid arthritis. The gene discussed is HDAC6; the disease is rheumatoid arthritis.